Ethical Considerations Explored for Aducanumab in Alzheimer Disease
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Access to Care Disrupted for Young Adults With Diabetes in COVID-19
Young adults with diabetes also report lower intention of receiving COVID-19 vaccination compared with those 60 years or older
AHA: Oral Milvexian Promising for Prevention of VTE
In patients undergoing knee arthroplasty, postoperative incidence of venous thromboembolism lower with milvexian versus enoxaparin
Physician’s Briefing Weekly Coronavirus Roundup
Strong Opioids No Better for Pain After Surgery for Fracture
No difference seen in Numerical Pain Rating Scale mean pain score for patients receiving strong versus mild opioids
Trial Begins of Nasal Vaccine for Alzheimer Disease
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
Nearly 10 Percent of Younger Children Have Gotten First COVID-19 Vaccine Dose
Children who get their first shot by the end of the week and their second one three weeks after will be fully vaccinated by Christmas
Moderna Asks FDA to Approve Its Booster Shot for All Adults
Moderna booster is half the dose of the initial vaccination series: 50 mcg versus 100 mcg
White House to Spend Billions to Boost COVID-19 Vaccine Supply
The goal of the plan is to produce at least 1 billion doses a year beginning in the second half of 2022
FDA Could Approve Pfizer Booster Shots for All Adults This Week
More than 30 million Americans have already gotten booster shots
